Neurogene Inc. (NGNE)
| Bid | 11.02 |
| Market Cap | 163.87M |
| Revenue (ttm) | 925K |
| Net Income (ttm) | -75.14M |
| EPS (ttm) | -4.28 |
| PE Ratio (ttm) | -2.68 |
| Forward PE | -2.07 |
| Analyst | Buy |
| Ask | 12.3 |
| Volume | 184,578 |
| Avg. Volume (20D) | 280,748 |
| Open | 10.75 |
| Previous Close | 10.77 |
| Day's Range | 10.50 - 11.54 |
| 52-Week Range | 6.88 - 74.49 |
| Beta | 1.47 |
About NGNE
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York....
Analyst Forecast
According to 5 analyst ratings, the average rating for NGNE stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 474.41% from the latest price.
Stock Forecasts
2 months ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNENEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advi...
